Clinical trial · Observational
Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma
Pre-Surgical Treatment or Radio Frequency Ablation (RFA) Evaluation of Future Remnant Liver Function Using Gd-EOB-DTPA Enhanced MRI in Patients Undergoing Hepatic Resection /RFA for Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether the global and segmental hepatic uptake and excretion of Gd-EOB-DTPA on Gd-EOB-DTPA-enhanced liver MRI correlates with standard liver function test results in the patients with Hepatocellular Carcinoma (HCC) before major hepatic resection or radiofrequency ablation (RFA).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver Dysfunction | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gd-EOB-DTPA | Drug | — | UNRESOLVED |
| MRI | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group 1: HCC resection/RFA
- description
- Patients who will undergo resection of at least two hepatic segments for HCC or radiofrequency ablation (RFA) for HCC and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
- interventionNames
- Drug: Gd-EOB-DTPA
- Procedure: MRI
- label
- Group 2: Potential liver donor
- description
- Potential liver donors with normal hepatic function and and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
- interventionNames
- Drug: Gd-EOB-DTPA
- Procedure: MRI
Primary outcomes (1)
- measure
- Correlation of hepatic extraction fraction (HEF) of future remnant liver function (RLF) obtained from Gd-EOB-DTPA enhanced MRI with postoperative ICG R15 clearance test results
- timeFrame
- 3 days (upto 5 days) after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with the diagnosis of HCC based on noninvasive diagnostic criteria of HCC proposed by 2010 AASLD 2. Surgical resection of hepatic resection greater than 2 Couinaud segments (including total hepatectomy for transplantation) or radiofrequency ablation is planned 3. Patients who provided the informed consent Exclusion Criteria: 1. Patients younger than 18 yrs old 2. Patients who received hepatic surgery prior to this study 3. Patients who underwent TACE or RFA for greater than 2 segments within 3 months prior to this study 4. Patients who received radiation treatment including the liver or systemic chemotherapy 5. Patients who underwent contrast enhanced liver MRI within 3 days prior to this study 6. Patients with severe renal dysfunction (Cr .2.5 mg/dL or GFR \< 30mL/min) 7. Patients with hypersensitivity to gadolinium 8. Patients with uncorrectable hypokalemia 9. Pregnant women, or reproductive age women who will not agree with contraception during this study period. 10. Patients with mental disorder which will interfere with voluntary agreement 11. Patients who have any contraindication to MRI (cardiac pacemaker, ferromagnetic implants, etc.) 12. Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the completion of the study.
References
Publications (1)
- DERIVEDYoon JH, Choi JI, Jeong YY, Schenk A, Chen L, Laue H, Kim SY, Lee JM. Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC. J Hepatol. 2016 Dec;65(6):1155-1162. doi: 10.1016/j.jhep.2016.07.024. Epub 2016 Jul 28. PMID 27476767